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Prognostic characteristics inform risk stratification in intensive care unit (ICU) patients with
coronavirus disease 2019 (COVID-19). We obtained blood samples (n= 474) from hospi-
talized COVID-19 patients (n= 123), non-COVID-19 ICU sepsis patients (n= 25) and healthy
controls (n= 30). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was
detected in plasma or serum (RNAemia) of COVID-19 ICU patients when neutralizing anti-
body response was low. RNAemia is associated with higher 28-day ICU mortality (hazard
ratio [HR], 1.84 [95% CI, 1.22–2.77] adjusted for age and sex). RNAemia is comparable in
performance to the best protein predictors. Mannose binding lectin 2 and pentraxin-3
(PTX3), two activators of the complement pathway of the innate immune system, are
positively associated with mortality. Machine learning identified ‘Age, RNAemia’ and ‘Age,
PTX3’ as the best binary signatures associated with 28-day ICU mortality. In longitudinal
comparisons, COVID-19 ICU patients have a distinct proteomic trajectory associated with
mortality, with recovery of many liver-derived proteins indicating survival. Finally, proteins of
the complement system and galectin-3-binding protein (LGALS3BP) are identified as inter-
action partners of SARS-CoV-2 spike glycoprotein. LGALS3BP overexpression inhibits spike-
pseudoparticle uptake and spike-induced cell-cell fusion in vitro.
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oronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2; a
single-stranded RNA virus) poses an unprecedented chal-
lenge to health care systems globally. It is increasingly apparent
that conventional prognostic scores for patients admitted to
intensive care units (ICUs) such as the Acute Physiology and
Chronic Health Evaluation (APACHE II) score1 and Sequential
Organ Failure Assessment (SOFA) score2, are unsuitable for
outcome prediction in COVID-19 ICU patients3–6.
In this context, circulating SARS-CoV-2 RNA (RNAemia) has
been highlighted as a promising prognostic marker in hospita-
lized COVID-19 patients, as it is associated with disease severity7
and mortality8–10, with an estimated prevalence of 10% (95% CI:
5–18%, random-effects model)7. Further, we hypothesized that
the acute and profound alterations in the innate and adaptive
immune system in COVID-19 patients3,11–13, especially in
RNAemic patients14–18, will be accompanied by marked changes
in the circulating proteome and interactome that will highlight
mechanistically relevant signatures and trajectories when com-
pared to non-COVID-19 sepsis and healthy controls. Thus far,
proteomics studies have focused on the determination of protein
markers of COVID-19 severity19–22, often with healthy indivi-
duals as a comparator, but have not assessed the longitudinal
relationship between proteomic changes, RNAemia, and 28-day
ICU mortality.
In this study, we assessed RNAemia, antibody response against
SARS-CoV-2, and proteomic profiles in serial blood samples from
COVID-19 patients admitted to two ICUs. Controls included
hospitalized, non-ICU patients with and without COVID-19 as
well as SARS-CoV-2-negative ICU sepsis patients. Sepsis is
defined as organ dysfunction caused by a dysregulated host
response to infection23,24. As SARS-CoV-2 infection causes organ
dysfunction (pulmonary and extrapulmonary)25,26 and there is
overlap in immunological changes between SARS-CoV-2 infection
and sepsis11,27, this formed the rationale for using SARS-CoV-2-
negative ICU sepsis patients as additional comparators. We
compared the associations of RNAemia and protein measure-
ments with 28-day ICU mortality, including established protein
markers of acute respiratory distress syndrome (ARDS), i.e., the
receptor for advanced glycation end-products (RAGE)28–30, and
prognosis in ICU patients with sepsis, i.e., pentraxin-3
(PTX3)31–34. In the context of RNAemia, we explored the
plasma protein interactions with the SARS-CoV-2 spike glyco-
protein, identifying galectin-3-binding protein (LGALS3BP) as a
novel binding partner with antiviral activities.
Results
Demographics and clinical characteristics of COVID-19
patients. 474 blood samples were available for analysis (Fig. 1,
Supplementary Fig. 1): 295 longitudinal samples from ICU
patients with COVID-19 admitted to two university hospitals
(GSTT; n= 62 and KCH; n= 16) and samples from hospitalized,
non-ICU COVID-19 patients for comparison (n= 45); ICU and
non-ICU patients without COVID-19 served as controls (n= 55).
The baseline clinical characteristics of all COVID-19 ICU patients
are shown in Supplementary Table 1. The primary outcome
measure was defined as mortality 28 days after ICU admission. As
expected35, non-survivors (23%) were older than survivors (P=
0.0004). COVID-19 patients admitted to ICU were pre-
dominantly males (72%). All other characteristics, including
common comorbidities, the time from symptom onset to ICU
admission, APACHE II score, and SOFA score, were similar
between ICU survivors and non-survivors. The mortality rate in
COVID-19 ICU patients was twice as high as in hospitalized,
Fig. 1 Schematic of study design. Plasma and serum samples were obtained from multiple patient cohorts across two UK-based university hospitals,
including 123 COVID-19 patients: 78 SARS-CoV-2 positive patients in ICU were sampled at multiple time points over a 2-week period and compared to
hospitalized non-ICU SARS-CoV-2 positive patients (n= 45). We used non-COVID-19 ICU patients (n= 25) and patients before undergoing elective
cardiac surgery (n= 30) as controls. Patient samples were assessed for SARS-CoV-2 RNAemia, antibody responses, and protein changes in the
circulation by data-independent acquisition (DIA) mass spectrometry (MS) analysis. Plasma protein interactions with SARS-CoV-2 spike glycoprotein were
determined using a pulldown assay followed by data-dependent acquisition (DDA) MS analysis. Functional effects of LGALS3BP were assessed in two
assays: SARS-CoV-2 spike-mediated cell-cell fusion (syncytia formation) and cell entry through SARS-CoV-2 spike pseudoparticle assays.
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non-ICU COVID-19 patients (23% vs. 11%; Supplementary
Table 2).
Frequency of SARS-CoV-2 RNAemia and association with
mortality in COVID-19 ICU patients. The presence of circu-
lating viral RNA was analyzed by reverse transcription-
quantitative polymerase chain reaction (RT-qPCR). Serum
(GSTT; n= 62) and plasma (KCH; n= 16) samples were col-
lected within 24 h of admission to ICU with COVID-19 and
thereafter during week 1, week 2, and again before discharge. Out
of 78, 18 (23%) COVID-19 ICU patients had detectable RNAemia
within the first 6 days of admission to ICU (Supplementary
Table 1). RNAemia was more common early after symptom onset
(Supplementary Fig. 2). RNAemia within 6 days of admission to
ICU was detectable in 56% of non-survivors but only in 13% of
survivors (P= 0.0006, Supplementary Table 1). RNAemia was
associated with a higher risk of 28-day mortality (hazard ratio
[HR], 2.05 [95% CI: 1.38–3.04]), that was comparable to age
(2.89 [1.66–5.03] Fig. 2a) and maintained after correction for age
and sex (HR, 1.84 [95% CI: 1.22–2.77], Fig. 2b). In comparison,
only 2 out of 45 (4%) non-ICU COVID-19 patients tested posi-
tive for RNAemia upon hospitalization (Supplementary Table 2).
General demographics and baseline clinical characteristics of
COVID-19 patients with and without RNAemia in the first 6 days
of admission to ICU are presented in Supplementary Table 3.
Hypertension (r= 0.33, P= 0.003), bilirubin (r= 0.32, P=
0.005), respiration rate (r= 0.27, P= 0.018), and elevated
potassium levels (r= 0.26, P= 0.023) were positively correlated
to RNAemia, while monocyte counts were inversely correlated
(r=−0.23, P= 0.047, Fig. 2c). Hierarchical clustering analysis of
all clinical variables and RNAemia is presented in Supplementary
Fig. 3. To confirm the specificity of our RT-qPCR assay, we
measured SARS-CoV-2 RNAemia in 134 plasma samples from 55
non-COVID-19 patients, all of which tested negative (Supple-
mentary Table 4).
Humoral immune response during SARS-CoV-2 RNAemia. In
COVID-19 ICU patients with detailed information on the days,
post-onset of symptoms (POS, n= 70), IgG antibodies to the S1
domain of SARS-CoV-2 spike glycoprotein and SARS-CoV-2
neutralizing capacity were measured by ELISA and Surrogate
Virus Neutralization Test36, respectively. The latter test evaluates
the inhibition of binding of the receptor-binding domain (RBD)
of SARS-CoV-2 spike to ACE2. COVID-19 ICU patients who
tested positive (n= 15) or negative (n= 55) for RNAemia within
the first six days in ICU showed no difference in their strong IgG
response to SARS-CoV-2 S1 or in their neutralization capacity
(Fig. 2d). However, when individual samples (n= 232) were
compared, RNAemia positive samples (n= 29) had lower anti-
SARS-CoV-2 spike IgG levels and lower SARS-CoV-2 neu-
tralization capacity (Fig. 2e).
Plasma proteome alterations in COVID-19 ICU patients. To
capture the host response of COVID-19 ICU patients, we inter-
rogated their plasma proteome. Baseline plasma samples from
COVID-19 ICU patients (KCH cohort, n= 12) were compared to
plasma samples from COVID-19-negative sepsis ICU patients
(sepsis, n= 12) and patients prior to undergoing elective cardiac
surgery (controls, n= 30) (Supplementary Table 4). The plasma
proteome was quantified by a data-independent acquisition–mass
spectrometry (DIA–MS) approach, using authentic heavy peptide
standards representing 500 proteins37, revealing 100 significantly
altered proteins across the three patient groups (q < 0.05) (Fig. 3a).
Hierarchical cluster analysis highlighted a cluster of 47 plasma
proteins enriched in COVID-19, including members of the
complement cascade, as well as proteins involved in platelet
degranulation, the acute phase response, and coagulation (Fig. 3a,
b).
Of the 100 circulating proteins altered across control, sepsis
ICU, and COVID-19 ICU patients, 29 overlapped with previous
proteomic reports identifying markers of COVID-19 severity19,20
(Supplementary Fig. 4). However, only a few were associated with
28-day mortality, as determined through DIA–MS analysis of
baseline serum samples obtained from a larger COVID-19 ICU
patient cohort (GSTT, n= 62) (Fig. 3c). Complement factor B
(CFB), carboxypeptidase N (CPN1), and alpha-1-antichymotrypsin
(SERPINA3) were all negatively associated with outcome but none
of these three associations remained significant after correcting for
multiple testing. An independent, publicly available dataset
utilizing proximity-extension assays in plasma (Olink Explore
1536, n= 264 survivors, n= 42 non-survivors, Fig. 4a, Supple-
mentary Table 5)38 also confirmed the lack of outcome association
for three other proteins identified as markers of COVID-19
severity in previous proteomics studies19,20: lipopolysaccharide-
binding protein, CD14, and inter-alpha-trypsin inhibitor heavy
chain H3 (ITIH3) (Fig. 3c).
Protein changes that emerged as significantly associated with
mortality in ICU patients but have not been previously linked to
the severity of COVID-19, included an elevation of mannose
binding lectin 2 (MBL2) and reductions in protein C (PROC),
plasminogen (PLG), coagulation factor 7 (F7) and vitamin D-
binding protein (GC) (Fig. 3d). A correlation matrix of clinical
variables and proteins associated with COVID-19 severity
(Fig. 3c) and outcome (Fig. 3c, d) measured in serum of the
GSTT cohort is presented in Supplementary Fig. 5.
Predictors of 28-day mortality in COVID-19 patients identi-
fied by machine learning. Next, we compared the predictive
performance of RNAemia against protein markers and clinical
characteristics for 28-day mortality in ICU patients. In the
external validation cohort of hospitalized COVID-19 patients
described above (n= 264 survivors; n= 42 non-survivors)38,
PROC and F7 were the only proteins associated with 28-day
mortality in our DIA–MS data (Fig. 3c, d) that were also mea-
sured by Olink proximity-extension assays38. Reduced PROC and
F7 were confirmed to be associated with 28-day mortality (Fig. 4a,
Supplementary Table 5)38. MBL2 was not part of the Olink panel
(Explore 1536) but MBL2 is known to form complexes with
PTX339. Interestingly, PTX3 emerged as one of the proteins most
strongly associated with mortality among 1472 unique proteins
measured in the external validation, outperforming most mea-
sured cytokines and chemokines, showing a larger fold change
than PROC or F7 (Fig. 4a, Supplementary Table 5)38. PTX3, a
protein we and others have previously highlighted as a prognostic
marker in ICU patients with sepsis31–34, also positively associated
with COVID-19 mortality in our ICU cohort when measured by
ELISA (Fig. 4b). In contrast, RAGE, an established protein
marker of ARDS28–30, remained unaffected by SARS-CoV-2
RNAemia and mortality (Fig. 4c, Supplementary Fig. 6a). PTX3
forms multimers that accumulated in the high molecular weight
fraction after high-performance size-exclusion chromatography
of plasma (Fig. 4d). PTX3 multimers correlated to neutrophil-
related proteins such as S100A8/A9, defensin (DEFA1), and
SERPINA3 as well as to monocyte/macrophage-related markers
such as CD1440 (Fig. 4e). A machine learning-based approach
was adopted to determine the best prognostic markers (Supple-
mentary Fig. 7). Based on statistical significance (P < 0.05, Fig. 4b,
Supplementary Table 1), age, RNAemia, urea, and PTX3 were
shortlisted as singleton markers. In non-survivors, PTX3 was
elevated (median circulating levels, 4.93 ng/ml [IQR: 2.78–6.20])
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23494-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:3406 | https://doi.org/10.1038/s41467-021-23494-1 | www.nature.com/naturecommunications 3
compared to survivors (median circulating levels, 2.16 ng/ml
[IQR: 1.41–3.64], P= 0.018, adjusted for age and sex) (Fig. 4b).
Although RNAemia surfaced as the best singleton predictor, its
sensitivity was low (Supplementary Table 6). Age was the next
best singleton predictor, however, its positive predictive value
(PPV) of 44% demonstrates low probability confidence in
predicting mortality. When binary combinations were analyzed,
two signatures emerged with comparable classification perfor-
mance: “Age, RNAemia” and “Age, PTX3” (Supplementary
Table 6). Although the triplet combination of age, FiO2, and
RNAemia achieved a ROC of ~86% with a sensitivity of 72.22%
and a specificity of 88.33% (Supplementary Table 6), the gain in
p=0.97 (age, sex corrected)
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PPV was nominal with no uplift in specificity when compared to
“Age, RNAemia”, suggesting the binary combination to be an
optimal signature to choose. The technical validation of our “Age,
RNAemia” model was undertaken using a permutation test for
statistical significance of the classifier performance (Supplemen-
tary Fig. 8a); and stability of feature importance in an alternate
machine learning feature ranking model, i.e., random forest
with resampling (Supplementary Fig. 8b). Kaplan–Meier plots
(Fig. 5) also illustrate that the binary combinations “Age,
RNAemia” (P < 0.0001) and “Age, PTX3” (P < 0.0001) provide
improved stratification.
Longitudinal protein associations with SARS-CoV-2 RNAemia
and clinical improvement. To explore whether the association of
RNAemia with 28-day mortality may reflect distinct pathological
processes, we identified proteins that associate with RNAemia at
baseline (Fig. 6a) and over time (Fig. 6b). Nine proteins were
significantly associated with RNAemia at baseline which included
an increase in plasma protease C1 inhibitor (SERPING1) and
complement component C4A (C4A); paralleled by a reduction in
VE-cadherin (CDH5) and CFH-related protein 1 (CFHR1)
(Fig. 6a). A correlation matrix of clinical variables and proteins
associated with RNAemia or outcome is presented in Supple-
mentary Fig. 5. In longitudinal serum samples from the GSTT
cohort (baseline, week 1 and week 2; n= 47), a greater increase of
polymeric immunoglobulin receptor (PIGR) was observed in
RNAemia positive, compared to RNAemia negative ICU patients
(Fig. 6b). In contrast, plasma kallikrein (KLKB1) levels sig-
nificantly increased over time but tended to be higher in
RNAemia negative ICU patients (Fig. 6b).
Hierarchical cluster analysis upon significantly changing serum
proteins over the two-week period (baseline, week 1 and week 2,
n= 47) revealed four distinct protein clusters (Fig. 6c), which
were annotated by gene ontology enrichment analysis. Alterations
in PIGR correlated closely with neutrophil degranulation proteins
such as S100A8 and S100A9 (Fig. 6c, Cluster 2), while KLKB1
kinetics followed members of the coagulation system such as F11
and SERPIND1 (Fig. 6c, Cluster 4). A comparison of the
trajectories of individual proteins between patients who survived
and died is shown in Supplementary Fig. 9. The most pronounced
changes were observed among proteins constituting cluster 3
(P= 0.003) and cluster 4 (P < 0.001) (Fig. 6c). L-selectin levels
(cluster 3) declined over time but were higher in patients who
survived (Supplementary Fig. 9). In contrast, the recovery of
many liver-derived proteins was suppressed in patients who died
(cluster 4), including apolipoproteins linked to lipid metabolism
(i.e., ApoB, ApoC1, and ApoE), biotinidase, complement factor
H (CFH), and kininogen (Supplementary Fig. 9). Significant
correlations between proteins constituting these clusters and
clinical variables are depicted in Supplementary Fig. 5.
LGALS3BP is enriched in COVID-19 and binds to SARS-CoV-
2 spike glycoprotein. To further explore potential mechanistic
links between RNAemia and circulating proteins, we searched for
binding partners of the SARS-CoV-2 spike glycoprotein. The
SARS-CoV-2 spike glycoprotein is the largest protein in the viral
envelope, responsible for cell entry, and is the main target of
neutralizing antibodies41. A magnetic affinity pulldown of a His-
tagged SARS-CoV-2 spike glycoprotein mixed with plasma from
COVID-19 ICU patients was coupled with proteomics to deter-
mine interaction partners. Proteomics analysis identified 28
spike-binding proteins after excluding contaminants and non-
specific binders (Fig. 7a, b, Supplementary Table 7). Eight of them
were immunoglobulins (Fig. 7a) and five were members of the
complement system, which are known to directly interact with
antigen-bound antibodies (i.e., C1 complement complex, Fig. 7b,
Supplementary Table 7). Additional interaction partners included
complement component 4-binding proteins alpha and beta
(C4BPA and C4BPB), CPN1 (among the proteins associated with
28-day mortality, Fig. 3c), and galectin-3-binding protein
(LGALS3BP). Apart from apolipoprotein D (APOD), LGALS3BP
was the only protein to be retrieved to a greater extent with spike
glycoprotein from plasma of COVID-19 ICU patients compared
to COVID-19-negative plasma (Fig. 7c, Supplementary Table 8).
LGALS3BP was markedly elevated in COVID-19 patients as
discovered by DIA-MS and confirmed by ELISA, but unchanged
between control and sepsis patients without COVID-19 (Fig. 7d).
Strikingly, LGALS3BP was among the most elevated proteins
when compared to sepsis ICU patients (Fig. 7e). Of the proteins
revealed to bind spike, only LGALS3BP and members of the
complement cascade were also specifically elevated in COVID-19
ICU patients. LGALS3BP abundance in COVID-19 patients
closely correlated with proteins and regulators of the complement
cascade (C6, C9, C4BPA, and C4BPB) (Fig. 7f, Supplementary
Fig. 10). While LGALS3BP rises with COVID-19 severity20,
LGALS3BP levels were not predictive for 28-day mortality and
declined over time (Fig. 3c, Supplementary Fig. 11). We,
therefore, explored the functional effects of LGALS3BP in cell-
based assays.
LGALS3BP impairs SARS-CoV-2 spike-mediated cell–cell
fusion and spike-pseudoparticle entry in vitro. SARS-CoV-2
spike induces cell-cell fusion (syncytia formation) when spike,
ectopically expressed on the membrane of host cells, binds to
ACE2 receptors of adjacent cells42–45. To test the effect of
LGALS3BP on spike-mediated syncytia formation, HEK293-ACE2
Fig. 2 SARS-CoV-2 RNAemia and the humoral immune response. a Unadjusted hazard ratios with 95% confidence interval (CI) based on two ICU patient
cohorts (n= 60 survivors and n= 18 non-survivors, KCH and GSTT). Green indicates P value < 0.05, maroon indicates P value < 0.001 and blue indicates
P value > 0.05. b, Hazard ratios with 95% CI after adjustment for age and sex (n= 60 survivors and n= 18 non-survivors, KCH and GSTT). c Association of
SARS-CoV-2 RNAemia with binary variables (Cohen’s Kappa correlation) and continuous variables (point-biserial correlation). Red indicates positive and
blue negative correlation with P value < 0.05. Abbreviations: Alb albumin, ALP alkaline phosphatase, ALT alanine aminotransferase, Bil bilirubin, COPD
chronic obstructive pulmonary disease, Crea creatinine, CRP C-reactive protein, DM diabetes, Hct hematocrit, Hb hemoglobin, HR heart rate, HTN
hypertension, Lymphoc lymphocytes, MAP mean arterial pressure, Monoc monocytes, Neutroph neutrophils, K+ potassium, Resp. rate respiratory rate, Na
+ sodium, Temp body temperature, WCC white cell count. d Anti-SARS-CoV-2 spike IgG and anti-SARS-CoV-2 neutralization response based on days
post-onset of symptoms (POS) in patients who tested positive (red) or negative (blue) for plasma/serum SARS-CoV-2 RNA within the first 6 ICU days
(261 samples from n= 55 RNAemia negative and n= 15 RNAemia positive patients). Lines show fitted generalized additive models (GAM) with gray bands
indicating the 95% CI, correcting for age and sex. e Anti-SARS-CoV-2 spike IgG levels and anti-SARS-CoV-2 neutralization capacity in individual samples
negative (232 samples) or positive (29 samples) for SARS-CoV-2 RNA (n= 70 patients). Lines inside violin plots show median (continuous line) and
interquartile range (dotted lines). Significance was determined through a Mann–Whitney U test. P values are corrected for age, sex, and days POS. All
statistical analyses are two-tailed.
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and Vero cells were transfected with an LGALS3BP-coding plas-
mid, followed by transfection of a SARS-CoV-2 spike-coding
plasmid 24 h later. Small interfering RNA (siRNA)-mediated
knockdown of ACE2 served as a positive control (siACE2), while
transfection of siNT1 (non-targeting control siRNA), pcDNA3
(plasmid backbone) and pmCherry (plasmid coding for mCherry)
served as negative controls (Fig. 8a). As expected, siACE2 signifi-
cantly reduced spike-mediated cell-cell fusion compared with
siNT1 (Fig. 8b–d). Strikingly, LGALS3BP overexpression also sig-
nificantly reduced cell–cell fusion compared with pcDNA3 and
pmCherry. This reduction in cell-cell fusion was dose-dependent
with increasing amounts of LGALS3BP plasmid (Supplementary
Fig. 12a–c). To rule out an effect of LGALS3BP on green fluor-
escent protein (GFP) expression, we co-transfected a GFP-coding
plasmid demonstrating that the LGALS3BP-coding plasmid had no
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Fig. 3 COVID-19 circulating proteome signature and associations with 28-day mortality. a Plasma proteome profiling was conducted using a data-
independent acquisition–mass spectrometry (DIA-MS) approach with spiked standards for 500 proteins. Hierarchical cluster analysis was conducted upon
significantly changing plasma proteins across control patients before elective cardiac surgery (n= 30), ICU patients with sepsis (n= 12), and ICU patients
with COVID-19 (n= 12, KCH). The heatmap highlights 47 proteins enriched in COVID-19. Kruskal–Wallis, Benjamini–Hochberg correction q < 0.05. b Gene
ontology enrichment analysis was conducted upon these 47 proteins and significantly enriched pathways are represented. c Twenty-nine common proteins
cross-referenced against two published proteomic studies, exploring protein markers of COVID-19 severity. The ability of these 29 proteins to predict
28-day mortality was explored in an independent ICU patient cohort (n= 62 patients, GSTT) by DIA–MS, and hazard ratios with 95% CI are shown.
d Proteomic analysis by DIA-MS conducted upon the serum samples of the GSTT COVID-19 ICU cohort returned additional candidates that predict 28-day
mortality as shown on hazard ratio plots with 95% CI (n= 62 patients, GSTT). Significance was determined through the Mann–Whitney U test, correcting
for age and sex and applying the Benjamini-Hochberg procedure. All statistical analyses are two-tailed.
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and knockdown of ACE2 was verified by immunoblotting in
HEK293-ACE2 cells (Supplementary Fig. 12f).
Next, we tested whether LGALS3BP affects the entry of
pseudoparticles carrying the spike protein in addition to a GFP
reporter, which is an established model of the SARS-CoV-2 entry
pathway46. For this purpose, we transfected HEK293-ACE2 with
an LGALS3BP-coding plasmid followed by the addition of
pseudoparticles 24 h later (carrying spike or vesicular stomatitis
virus G (VSV-G) protein as a control). siACE2 served as a
positive control, while transfection of siNT1 and pcDNA3 served
as negative controls (Fig. 8e). As expected, siACE2 significantly
reduced cellular uptake of spike-pseudoparticles compared with
siNT1 (Fig. 8f, g), while uptake of VSV-G particles remained
unaffected (Fig. 8f, h). Strikingly, LGALS3BP overexpression also
significantly reduced uptake of spike-pseudoparticles compared
with pcDNA3 (Fig. 8f, g), while VSV-G uptake remained
unaffected (Fig. 8f, h). In contrast, we did not observe a
significant reduction in spike-pseudoparticle uptake when spike-
pseudoparticles were pre-incubated with the supernatant from
LGALS3BP-expressing cells (Supplementary Fig. 13a–c).
Discussion
The main findings of our study include a 23% prevalence of
SARS-CoV-2 RNAemia in ICU patients with COVID-19, an
independent association of SARS-CoV-2 RNAemia with risk of
28-day mortality, and a proteomic trajectory characterized by
four distinct protein clusters which mirrored the clinical status.
Furthermore, we performed pulldown experiments with SARS-
CoV-2 spike glycoprotein identifying LGALS3BP and comple-
ment system proteins as potential interaction partners. We
highlight that overexpression of LGALS3BP impaired SARS-
CoV-2 spike glycoprotein-induced syncytia formation and spike-
pseudoparticle transduction efficiency.
SARS-CoV-2 RNAemia was observed in 23% of COVID-19
ICU patients within the first six days of admission to ICU, which
is more frequent than its estimated prevalence (10% [95% CI:
5–18%], random-effects model)7. Likely explanations include:
first, the fact that RNAemia is expected to be more common in
ICU patients due to disease severity7. Second, we optimized
detection by performing a two-step RT-qPCR protocol rather























































































































































































Fig. 4 External protein marker validation and PTX3 selection. a PTX3 was among the proteins most strongly associated with poor outcome among 1472
unique plasma proteins (Data provided by the MGH Emergency Department COVID-19 Cohort (Filbin, Goldberg, Hacohen) with Olink Proteomics)38. Of
the 10 proteins we found to be associated with outcome in our DIA–MS data (Fig. 3c, d), PROC and F7 were the only proteins also measured in the external
validation data, confirming an inverse association with mortality. The log2FC (adjusted for categorical age) was higher for PTX3: 0.8, adjusted P value=
0.00044 compared with PROC: −0.4, adjusted P value= 0.0006 and F7: −0.3, adjusted P value= 0.03. b PTX3 measurements by ELISA (KCH and GSTT
samples for COVID-19-ICU cohorts in left and right panel, respectively). c ELISA measurements for RAGE, as an established marker for ARDS. d High-
performance liquid chromatography (HPLC) fractionation of plasma (n= 35-time points from 13 patients, KCH). PTX3-containing high molecular weight
(HMW) fraction is shaded in gray. A280 denotes the absorbance of the eluent at 280 nm. e Proteomics analysis of the HMW fraction. Significant Spearman
correlations of PTX3 with neutrophil- and macrophage-related proteins. All statistical analyses are two-tailed.
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which RNAemia has been assessed thus far. Third, RNAemia was
more frequent closer to the onset of symptoms7 and when
humoral response against SARS-CoV-2 was low. The latter
observation was maintained after correcting for time since onset
of symptoms. Thus, this is not a mere reflection of low humoral
response in early sampling points. Using droplet digital PCR15,
RNAemia might become even more frequent but the clinical
relevance of very low levels of RNAemia is unclear.
RNAemia within 6 days of ICU admission was strongly asso-
ciated with 28-day mortality, which is a well-defined outcome
measure in clinical trials5,47. Thus far, studies on RNAemia
included predominantly non-ICU patients and associated
RNAemia with disease severity7. Few studies also reported on the
ability of RNAemia to predict mortality8–10 but none of these
studies specifically focused on ICU patients in which RNAemia is
likely to be most informative. Our study focused on COVID-19
ICU patients (n= 78) with 28-day mortality as an outcome and
included hospitalized, non-ICU COVID-19 patients (n= 45) as
well as non-COVID-19 patients (n= 55). In comparison to
RNAemia as assessed in our study (HR, 1.84 [95% CI: 1.22–2.77]
adjusted for age and sex), the mortality risk conferred by
increased nasopharyngeal SARS-CoV-2 RNA levels was found to
be small (HR, 1.07 [95% CI: 1.03–1.11], n= 1145)48. Correlation
between nasopharyngeal and plasma viral load was previously
found to be of moderate strength (r= 0.32)9, suggesting that the
viral load in the nasopharyngeal compartment only accounts for a
minor part (r2= 10.2%)9 of the plasma variation. Thus, other
pathological processes are likely to contribute to RNAemia,
independent of viral load. RNAemia could be a consequence of
severe disease and might reflect the extent of viral dissemination.
Notably, serum levels of CDH5, an endothelial-specific surface
protein, differed between RNAemia positive versus negative ICU
patients. RNAemia was also inversely associated with monocyte
counts. A decrease in monocyte counts in COVID-19 patients has
been attributed to extravasation and recruitment to lungs11,49.
Similar to previous studies on RNAemia, the proteomic studies
published to date focused on hospitalized COVID-19 patients.
Proteome changes were associated with disease severity and
healthy individuals were often used as controls19–22. In our study
we highlight that few of the plasma protein changes associated
with disease severity also predict outcome in ICU patients who
are already critically ill, and included pre-pandemic sepsis ICU
patients as an additional control. An argument could be made for
using ARDS controls, due to similarities between non-COVID-19
ARDS and COVID-19 ARDS that we have previously
reported3,50. However, in addition to our rationale for non-
COVID-19 sepsis controls highlighted earlier, all sepsis patients
used as controls were mechanically ventilated51; would meet the
consensus definitions of ARDS52; and could have been enrolled in
clinical trials of ARDS53, since the most common etiology of
ARDS is infection. The validation of the trajectory of differentially
expressed proteins in COVID-19 and their association with
outcome was done in serum samples of the larger GSTT COVID-
19 ICU cohort (n= 62). The Olink measurements in the external
Fig. 5 SARS-CoV-2 mortality prediction using machine learning. a Kaplan–Meier plot for age (using the median age of 54 years). b Kaplan–Meier plot for
SARS-CoV-2 RNAemia. As a single predictor, RNAemia provides the best stratification for survival. c Kaplan–Meier plot for PTX3 using the median levels of
serum or plasma. d–f Kaplan–Meier plots for “RNAemia, PTX3”, “Age, RNAemia”, and “Age, PTX3” combined using support vector machine with radial
basis function kernel (SVM RBF), a non-linear machine learning model. The machine learning model selected binary combinations of “Age, RNAemia” and
“Age, PTX3” as the best predictors. Kaplan–Meier analysis is two-tailed. Nonsurvivors: n= 18; survivors: n= 60.
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validation cohort were performed in plasma (Fig. 4a). Validation
in plasma and in serum ensures that the protein changes are
independent of the sample type, which is important for the
clinical applicability of findings. The Olink platform covered two
(of ten) proteins (PROC, F7) associated with 28-day mortality
measured by our DIA-MS approach, highlighting the com-
plementarity of these different proteomics methods54.
Our proteomics data reveal that complement activation is a core
component of the overreaction of the immune system in response
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28-day ICU mortality (Fig. 3d). Systemic complement activation
has been associated with respiratory failure in hospitalized
COVID-19 patients55, and complement deficiencies appear to
have protective effects on COVID-19-associated morbidity and
mortality56. Similarly, C3 deficient mice developed less respiratory
dysfunction following SARS-CoV infection57. It was recently
reported58 that circulating complement factors are high before
seroconversion, while markers of systemic complement activation
decrease after seroconversion, although this particular study did
not include patients admitted to ICU with life-threatening
Fig. 6 Circulating protein changes associated with SARS-CoV-2 RNAemia over time. a DIA–MS analysis upon serum samples from the GSTT COVID-19
ICU cohort was used to determine proteins that associate with the presence of SARS-CoV-2 RNAemia at baseline (n= 9 positive, n= 38 negative).
Proteins that were significantly associated with RNAemia at baseline are individually represented as violin plots. Significance was determined through the
Limma linear model analysis using Benjamini and Hochberg’s FDR correction. b Proteins with significantly different trajectories over time (baseline, week 1
—time point 1, week 2—time point 2) between RNAemia positive and negative patients (n= 9 positive patients, n= 38 negative patients with samples in
each of the three-time points, totaling n= 141 samples). PIGR polymeric immunoglobulin receptor, KLKB1 kallikrein B1. The median and 95% CI of the
median is shown. Unadjusted for multiple comparisons. c Serial serum samples from COVID-19 ICU patients (GSTT, baseline, week 1 and week 2, n= 10
nonsurvivors, n= 37 survivors with samples in each time point, totaling 141 samples) were analyzed by DIA–MS to determine protein changes over time in
ICU. The heat map represents a hierarchical cluster analysis conducted upon a Spearman correlation network of significantly changing proteins over time in
ICU, applying row-wise corrections for multiple testing using the Benjamini-Hochberg FDR correction. Comparison of the trajectories of protein clusters
in COVID-19 ICU patients based on 28-day mortality is also shown. Gene ontology enrichment analysis was used to determine functional pathways
associated with the distinct protein clusters identified. Listed are the protein clusters that show a significant change between 28-day survivors (gray) and
nonsurvivors (red)—and having significant interaction with time points (baseline, week 1—time point 1, week 2—time point 2). Lines show nonlinear
regression curves with gray bands indicating the 95% CI. P values represent the significance of the outcome term in a fitted GAM model when correcting
for age and sex. All statistical analyses are two-tailed.















































































































































































































Fig. 7 LGALS3BP interacts with SARS-CoV-2 spike glycoprotein. a Magnetic bead-based affinity isolation of binding partners using His-tagged SARS-
CoV-2 spike glycoprotein as a bait for proteins in SARS-CoV-2-positive patient plasma (n= 8). Volcano plot depicting significantly enriched constant
chains of immunoglobulins. b Volcano plot depicting significantly enriched non-immunoglobulin proteins (n= 8). c Comparison of SARS-CoV-2 spike
glycoprotein pulldown using plasma from COVID-19 ICU patients (n= 8) and non-COVID-19 patients (n= 3). Significance was determined by paired
Student’s t tests for (a) and (b) and unpaired Student’s t tests for (c). d LGALS3BP levels across three patient cohorts as determined by DIA-MS or ELISA:
control patients before undergoing elective cardiac surgery (n= 30), pre-pandemic sepsis ICU patients (n= 12) and COVID-19 ICU patients (n= 74).
Kruskal–Wallis and Dunn’s multiple comparisons tests were used to determine statistical significance. e Volcano plot representing protein changes
between baseline plasma samples from patients in ICU with either sepsis (n= 12) or COVID-19 (n= 12). Significance was determined through the
Mann–Whitney U test with Benjamini-Hochberg’s FDR correction. f Plasma proteins correlating to LGALS3BP after age and sex corrections in COVID-19
ICU patients (n= 12) are highlighted by a Spearman correlation matrix across the proteomic dataset. Proteins with a Spearman correlation coefficient
greater than 0.5 were used for gene ontology pathway enrichment analysis (Supplementary Fig. 10). All statistical analyses are two-tailed.
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COVID-1958. Interestingly, patients with RNAemia (Fig. 6a)
showed dysregulation in several components of the complement
(SERPING1, C4A, and CFHR1), the coagulation (F5) and the
kinin-kallikrein system (KLKB1). Combined activation of these
pathways is a hallmark of thromboinflammation59,60.
Viral envelope glycoproteins are known to be an important
trigger of the contact pathway of coagulation59 and the comple-
ment system61. MBL2 binds to glycoproteins on the viral
surface62,63 and is a key molecule for the lectin pathway of
complement activation in the circulation64. MBL2 levels were
markedly elevated in COVID-19 ICU patients who died. High
levels of MBL2 have previously been associated with lectin
pathway-mediated tissue damage65,66. Furthermore, we found
MASP1, the downstream mediator of MBL2, to be increased in
plasma from COVID-19 ICU patients compared with sepsis
patients. Moreover, PTX3 is important for activation (through
MBL2 and C1q)39 and regulation (through CFH and C4BPB)67,68
of the complement system64,69. The MBL2/PTX3 complex can
directly activate the complement system independent of antigen-
antibody complexes. Consistent with our previous results on
PTX3 in sepsis patients31,70, PTX3 also emerged as a strong
predictor for mortality in COVID-19 ICU patients. This is in
agreement with other studies38,40,71 reporting strong associations
of PTX3 with COVID-19 mortality71. PTX3 is released from
neutrophils upon activation70,72, is abundant in macrophages40,
but also highly expressed in lung and adipose tissue (www.
gtexportal.org/home/gene/PTX3). While anti-SARS-CoV-2 anti-
body levels were similar in COVID-19 ICU patients who survived
and died, MBL2 and PTX3 were associated with poor outcome
pointing towards the importance of antibody-independent
mechanisms of complement activation in COVID-19. Clinical
trials with complement inhibitors are currently ongoing for
COVID-1959.
Besides members of the complement system, we demonstrate
that LGALS3BP is a novel binding partner of SARS-CoV-2 spike
glycoprotein. However, the direct interaction between LGALS3BP
and SARS-CoV-2 spike remains to be confirmed as pulldown
assays cannot rule out indirect binding to the bait protein.
Interestingly, the N-terminal domain of the SARS-CoV-2 spike
glycoprotein is highly homologous to human galectin-373, which
may explain the interaction we observed with LGALS3BP. The
presence of this 13-strand beta-sheet domain is not unique to the
SARS-CoV-2 spike as it is also present in the spike glycoproteins
of other members of the Betacoronavirus genus74. It has been
proposed that this galectin domain was acquired from host cells
and provided the virus with another cell attachment mechanism
in its arsenal thus presenting an evolutionary advantage75. Thus,
it has been suggested that galectin-3 inhibitors may be useful in
the treatment of COVID-1973,76. LGALS3BP is prominently
expressed in the lung77, but also adipose tissue (www.gtexportal.
org/home/gene/LGALS3BP) and possesses antiviral activity78.
The rise in circulating LGALS3BP is not observed in non-
COVID-19 sepsis ICU patients, highlighting the specificity for
viral over bacterial infections. LGALS3BP directly interacts with
adeno-associated viruses, inducing viral particle aggregation and
impairment of transduction79. LGALS3BP also reduces the
infectivity of human immunodeficiency virus (HIV) particles80.

























































































Fig. 8 LGALS3BP overexpression impairs SARS-CoV-2 spike-mediated syncytia formation and cellular uptake of SARS-CoV-2 spike-pseudoparticles.
a Schematic representation of the SARS-CoV-2 spike-mediated cell-cell fusion assay. b–d Vero and HEK293-ACE2 cells were transfected either with
pcDNA3 (plasmid backbone), pmCherry (plasmid coding mCherry), pLGALS3BP (plasmid coding LGALS3BP), siACE2 (siRNA targeting ACE2), or siNT1
(non-targeting siRNA), followed by transfection of pAAV-Spike (plasmid coding SARS-CoV-2 spike) 24 h later. After 20 h, cells were stained with anti-
LGALS3BP (violet), anti-Spike (green), and DAPI for nuclei (blue). Representative images are shown in (b), and quantifications are shown in (c) for Vero
cells and in (d) for HEK293-ACE2 cells. Data (mean ± standard deviation; n= 6; Mann–Whitney U test) are plotted as the percentage of fused cells
(syncytia) normalized to the total number of cells. Scale bars in (b) represent 100 µm. e Schematic representation of the SARS-CoV-2 spike/VSV-G
pseudoparticle transduction assay. f–h HEK293-ACE2 cells were transfected either with pcDNA3, pLGALS3BP, siACE2, or siNT1, followed by the addition
of spike- or VSV-G pseudoparticles carrying a GFP reporter 24 h later. After 36 h, cells were stained with anti-LGALS3BP (red), anti-GFP (green), and DAPI
for nuclei (blue). Representative images are shown in (f) and quantifications are shown in (g) for spike-pseudoparticles (mean ± standard deviation; n= 6;
Mann–Whitney U test) and in (h) for VSV-G pseudoparticles (mean ± standard deviation; n= 3). Data are plotted as the percentage of GFP-positive cells
normalized to the total number of cells. Scale bars in (f) represent 200 µm. All statistical analyses are two-tailed.
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intracellular effects80. Similarly, the supernatant from
LGALS3BP-overexpressing cells did not inhibit SARS-CoV-2
spike-pseudoparticle entry. However, LGALS3BP overexpression
reduced spike-mediated syncytia formation, and decreased spike-
pseudoparticle entry, which are two functional readouts that we
have recently used for drug discovery in COVID-1945. Thus,
LGALS3BP may impede SARS-CoV-2 also through extracellular
effects. LGALS3BP may be bound to the extracellular surface of
the plasma membrane, similarly to other secreted proteins such as
fibroblast growth factor-281 and HIV-1 tat protein82. The possi-
bility of LGALS3BP binding to carbohydrates on the extracellular
surface could explain its antiviral effects83.
In summary, we report that RNAemia in COVID-19 ICU
patients is associated with a higher risk of death, an observation
that could potentially be a disease-specific enrichment
biomarker84 for antiviral medications, given the lack of benefit of
these drugs in unselected ICU patients with COVID-1985. Pro-
teomics analyses of blood samples from ICU patients with
COVID-19 uncovered protein trajectories that mirror the recently
reported immune trajectory in COVID-19 and add further
granularity to COVID-19 biology, in particular with regard to
complement activators of the innate immune system (MBL2/
PTX3) being associated with mortality; and recovery of several
liver-derived proteins being linked to survival86. Finally, our
observation that LGALS3BP is a novel interaction partner of the
SARS-CoV-2 spike glycoprotein has potential therapeutic
implications.
Methods
Study design and recruitment. An overview of the study design is presented in
Supplementary Fig. 1. COVID-19 cohorts: COVID-19-positive patients, as con-
firmed by RT-qPCR of nasopharyngeal samples, who were admitted to the ICUs of
Guy’s and St Thomas’ NHS Foundation Trust (GSTT) and King’s College Hospital
(KCH) between March 12, 2020, and July 1, 2020, were recruited for an obser-
vational cohort study with serial blood sampling and analysis of clinical outcomes.
The primary outcome measure was defined as mortality 28 days after ICU
admission. Serial blood sampling was performed within 24 h of admission to ICU
and thereafter three measurements were taken during week 1, week 2, and again
before discharge. In addition, we obtained plasma samples from COVID-19
patients upon hospitalization at GSTT (non-ICU COVID-19 cohort). Non-
COVID-19 comparator cohorts: Plasma was collected from patients enrolled at the
same time in the same KCH ICU as our COVID-19 ICU cohort but who repeatedly
tested negative for nasopharyngeal SARS-CoV-2 (intra-pandemic, non-COVID-19
ICU cohort). Serial blood sampling of these samples was performed identically to
our COVID-19 cohort. Additionally, pre-pandemic plasma samples from patients
recruited at GSTT prior to the COVID-19 pandemic were available as controls.
Firstly, this included serial plasma samples from sepsis ICU patients (pre-pan-
demic, non-COVID-19 ICU sepsis cohort) recruited between October 16, 2019,
and February 26, 2020, collected upon admission and at three-time points there-
after. Sepsis was defined according to Sepsis-3 definitions (infection with organ
dysfunction defined using SOFA score 2 or more points). The eligibility criteria for
this cohort and the study protocol have been reported before51. Secondly, plasma
samples from patients before elective cardiac surgery (pre-pandemic, non-COVID-
19 control cohort) recruited between July 8, 2019, and September 9, 2019. The
study was approved by an institutional review board (REC19/NW/0750 for all
patients recruited at KCH; REC19/SC/0187 for patients recruited at GSTT of the
COVID-19 ICU cohort, the pre-pandemic sepsis ICU cohort, the pre-pandemic
control cohort; REC19/SC/0232 for patients recruited at GSTT of the non-ICU
COVID-19 cohort). Written informed consent was obtained directly from patients
(if mentally competent), or from the next of kin or professional consultee. The
consent procedure was then completed with retrospective consent if the patient
regained capacity.
Inactivation of serum and plasma. Plasma was collected in EDTA BD Vacutai-
nerTM tubes (BD, 362799), whereas serum was collected in silica BD VacutainerTM
tubes (BD, 367820) and left to clot for 15 min. Plasma and serum tubes were then
centrifuged at 2000×g for 15 min. Infectious samples were then transferred to a
containment level 3 facility for safe inactivation. Samples destined for RNA
extraction were inactivated by the addition of 100 µL of serum or plasma to 500 µL
QIAzol (Qiagen, 79306), followed by 40 s of vortexing and 5 min incubation at
room temperature. Samples destined for protein analysis were inactivated by the
addition of 1% (v/v) Triton X-100 (Sigma, T8787) and 1% (v/v) tributyl phosphate
(Sigma, 00675), followed by 15 s of vortexing and 4 h incubation at room
temperature. Heat treatment was not performed to avoid protein precipitation. All
samples were then frozen at −80 °C until further processing.
High-performance liquid chromatography fractionation of plasma. High-
performance size-exclusion chromatography of the KCH plasma samples (n= 35,
from 13 patients) was performed using a TSKgel® G5000PWXL column (hydro-
xylated methacrylate, 10 µm particle size, 100 nm mean pore size; Tosoh
Bioscience, 0008023) equipped with a TSKgel® PWXL guard column (hydroxylated
methacrylate, 12 µm particle size, mixed pore size; Tosoh Bioscience, 0008033).
Totally, 20 µL plasma was fractionated with PBS as a mobile phase at a flow rate of
0.6 ml/min. The high molecular weight (HMW) fraction (7.86–8.96 ml eluent) was
denatured, reduced, alkylated, digested, and DDA–MS was performed.
RNA extraction and heparinase treatment. Total RNA was extracted using the
miRNeasy Mini kit (Qiagen, 217004) according to the manufacturer’s recom-
mendations. Total RNA was eluted in 30 µL of nuclease-free H2O by centrifugation
at 8500×g for 1 min at 4 °C. To overcome the confounding effect of heparin on
qPCR87,88, RNA was treated with heparinase89. Briefly, 8 µL of RNA was added to
2 µL of heparinase 1 from Flavobacterium (Sigma, H2519), 0.4 µL RNase inhibitor
(Ribo Lock 40 U/µL, ThermoFisher, EO0381) and 5.6 µL of heparinase buffer
(pH 7.5) and incubated at 25 °C for 3 h.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). For
detection of SARS-CoV-2 RNA we performed a two-step RT-qPCR using the
LunaScript® RT SuperMix Kit (NEB, E3010) and the Luna Universal Probe qPCR
Master Mix (NEB, M3004) according to the manufacturer’s recommendations,
apart from reducing the total qPCR reaction volume to 5 µL and loading a cDNA
dilution of 1:4 instead of 1:8 when performing the qPCR reaction. Primer/probe
sequences targeting the SARS-CoV-2 nucleocapsid (N) gene (N1 and N2) were
predesigned by Integrated DNA Technologies (IDT, 10006821, 10006822,
10006823, 10006824, 10006825, and 10006826) according to the protocol for the
detection of SARS-CoV-2 of the United States Centers for Disease Control and
Prevention (US CDC), using 5′ FAM/ZEN™/3′ Iowa Black™ FQ probes (Supple-
mentary Table 9). The qPCR reaction concentration for probe (125 nM), forward
(500 nM) and reverse primers (500 nM) were used according to the US CDC
protocol. A plasmid positive control (2019-nCoV_N Positive Control plasmid,
IDT, 10006625) was measured on each qPCR plate. Reactions were loaded using a
Bravo Automated Liquid Handling Platform (Agilent). qPCR was performed on a
ViiA7 Real-Time PCR System (Applied Biosystems). Samples were considered
positive for SARS-CoV-2 if the cycle quantification (Cq) value of either N1 or N2
was below 40. The abundance of SARS-CoV-2 RNA in patients who tested positive
had a mean Cq of 34.4; range: 29.8–37.6. As reported before90, N1 primers returned
lower Cq values (higher abundance) than N2 primers (Supplementary Fig. 14).
Measurement of anti-SARS-CoV-2 antibodies. IgG antibodies against the SARS-
CoV-2 spike S1 domain were measured by ELISA (Anti-SARS-CoV-2 IgG ELISA,
Euroimmun, EI 2606-9601G) according to the manufacturer’s recommendations.
Since no international reference serum for anti-SARS-CoV-2 antibodies exists,
calibration was performed in ratios, giving relative antibody quantification. Neu-
tralizing antibodies against SARS-CoV-2 were measured using a Surrogate Virus
Neutralization Test (SARS-CoV-2 sVNT Kit, GenScript, L00847)36 according to
the manufacturer’s recommendations. This ELISA-based kit detects antibodies that
are able to block the interaction between the SARS-CoV-2 spike RBD and the
angiotensin-converting enzyme (ACE2) cell receptor. For technical validation of
sVNT measurements in a subset of samples (38 samples from 16 ICU patients),
neutralization potency was measured using HIV-1 (human immunodeficiency
virus-1) based virus particles, pseudotyped with SARS-CoV-2 spike protein in a
HeLa cell line stably expressing the ACE2 receptor13. Briefly, serial dilutions of
serum samples were prepared with Dulbecco’s Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin; and
incubated with pseudotype virus for 1 h at 37 °C in 96-well plates. The HeLa cells
stably expressing the ACE2 receptor (provided by J. Voss, Scripps Research) were
then added (12,500 cells per 50 μL per well) and the plates were incubated for 72 h.
Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit
(Promega), using a Victor X3 Multilabel Reader (Perkin Elmer). Measurements
were performed in duplicate and duplicates were used to calculate the ID50. In this
technical validation, a significant positive correlation was obtained for values
returned by both assays (r= 0.81, P < 0.0001).
In-solution protein digestion. Totally, 10 µL of inactivated serum or plasma were
denatured by the addition of urea (final concentration 7.2 M) and reduced using
dithiothreitol (final concentration 5 mM) for 1 h at 37 °C and shaking at 180 rpm.
Reduced proteins were cooled down to room temperature before being alkylated in
the dark for 1 h using iodoacetamide (final concentration 25 mM). An aliquot
equivalent to 40 µg of alkylated protein was added to a 0.1 M triethylammonium
bicarbonate solution (pH 8.2) and digested for 18 h at 37 °C, shaking at 180 rpm
using 1.6 µg of Trypsin/LysC (Promega, V5072). Digested peptide solutions were
acidified using trifluoroacetic acid (TFA, final concentration 1%).
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Peptide clean-up and stable isotope-labelled standard (SIS) spike-in. Peptide
clean-up was achieved using a Bravo AssayMAP Liquid Handling Platform (Agi-
lent). After conditioning and equilibration of the resin, acidified peptide solutions
were loaded onto AssayMAP C18 Cartridges (Agilent, 5190-6532), washed using
1% acetonitrile (ACN), 0.1% TFA (aq) and eluted using 70% ACN, 0.1% TFA (aq).
Eluted peptides were vacuum centrifuged (Thermo Scientific, Savant SPD131DDA)
to dry and resuspended in 40 µL of 2% ACN, 0.05% TFA (aq). For clinical cohort
analysis, 6 µL of cleaned peptide solution was added to two injection equivalents of
PQ500 SIS mix (Biognosys, Ki-3019-96) using a Bravo Liquid Handling Platform
(Agilent).
DIA–MS analysis. Peptides were analyzed using a high-performance liquid
chromatography (HPLC)–MS assembly consisting of an UltiMate 3000 HPLC
system (Thermo Scientific) which was equipped with a capillary flow selector and
coupled via an EASY-Spray NG Source (Thermo Scientific) to an Orbitrap Fusion
Lumos Tribrid mass spectrometer (Thermo Scientific). To generate DIA data for
serum samples (GSTT COVID-19 ICU cohort) and plasma samples (KCH
COVID-19 ICU cohort, the pre-pandemic sepsis ICU cohort and the pre-pandemic
control patients before elective cardiac surgery), peptides were injected onto a C18
trap cartridge (Thermo Scientific, 160454) at a flow rate of 25 µL/min for 1 min,
using 0.1% formic acid (FA, aq). The initial capillary flow rate was reduced from 3
to 1.2 µL/min in 1 min at 1% B. Peptides were then eluted from the trap cartridge
and separated on an analytical column (Thermo Scientific, ES806A, at 50 °C) using
the following gradient: 1–11 min, 1–5% B; 11–32 min, 5–18% B; 32–52 min,
18–40% B; 52–52.1 min, 40–99% B; 52.1–58 min, 99% B. The flow rate was
increased to 3 µL/min and the column was washed using the following gradient:
58–58.1 min, 99–1% B; 58.1–59.9 min, 1–99% B; 59.9–60 min, 99–1% B. Finally,
the column was equilibrated at 1% B for 6 min. In all HPLC-DIA-MS analyses,
mobile phase A was 0.1% FA (aq) and mobile phase B was 80% ACN, 0.1% FA
(aq). Precursor MS1 spectra were acquired using Orbitrap detection (resolution
60000 at 200 m/z, scan range 329–1201 m/z). Quadrupole isolation was used to
sequentially scan 30 precursor m/z windows of variable width (Supplementary
Table 10). Per isolation window, semi-targeted Orbitrap MS2 spectra (resolution
30000 at 200 m/z) were collected following higher-energy C-trap dissociation.
MS database search for DIA–MS analysis. PQ500 SIS-spiked DIA data from all
serum and plasma samples of the GSTT COVID-19 ICU cohort, the KCH COVID-
19 ICU cohort, the non-COVID-19 sepsis ICU cohort and the control patients
before elective cardiac surgery were analyzed in Spectronaut v14 (Biognosys AG),
using the provided PQ500 analysis plug-in. MS1 and MS2 mass tolerance strategies
were set to dynamic. Retention time calibration was achieved using the spiked iRT
peptides included in the PQ500 SIS mix. Precursor and protein Q-value cutoff was
set to 0.01. Quantification was conducted at an MS2 level using peak areas and
individual runs were normalized using the global strategy set to the median. All
peptides for reported proteins were manually checked to ensure accurate peak
integration across all samples. Peptides with a Q-value of more than 0.01 or a signal
to noise ratio of less than 5 were marked as missing. Peptides with more than 30%
missing values across all samples were filtered out and the remaining missing
values were imputed using the K nearest neighbours (KNN) algorithm (K= 5)91.
Spearman correlations of peptides belonging to the same protein were computed.
In case more than two peptides per protein were detected, peptides were filtered if
their correlation with the remaining peptides was less than r= 0.4. In case two
peptides per protein were detected, the most abundant peptide was kept even when
correlation was less than r= 0.4. Final protein abundance was calculated by
summing up the quantified peptide abundances. Final quantitative comparisons
were conducted using the light/heavy peptide abundance ratio. For validation of
our DIA-MS data, we correlated levels to clinical measurements of albumin (n=
49, r= 0.68, P < 0.05) and C-reactive protein (n= 49, r= 0.83, P < 0.05) as
examples of high and medium-abundant proteins.
Enzyme-linked immunosorbent assay (ELISA). ELISAs for receptor for
advanced glycation end-products (RAGE; R&D Systems, DRG00), galectin-3-
binding protein (LGALS3BP; R&D Systems, DGBP30B), and pentraxin-3 (PTX3;
Abcam, ab214570) were performed according to the manufacturer’s instructions.
SARS-CoV-2 spike protein pulldown. His-tagged recombinant SARS-CoV-2
spike glycoprotein (RP-87680, ThermoFisher) was added to 1:2 PBS-diluted plasma
from COVID-19 ICU patients (n= 8) or non-COVID-19 controls (n= 3) at
200 ng/µL and incubated overnight at 4°C with intermittent mixing. His-tagged
spike was then isolated by means of metal affinity magnetic beads (Dynabeads His-
Tag Isolation and Pulldown, 10103D, ThermoFisher) and eluted in imidazole-
containing phosphate buffer. Proteins in the pulldown isolates were denatured,
reduced, alkylated and precipitated, as described above. Proteins interacting non-
specifically with the solid phase were determined by incubating plasma samples
with magnetic beads without the addition of His-tagged spike. Pulldown of
His-tagged spike without the addition of plasma was performed as an additional
control. Spike pulldown protein digestion followed the same protocol
outlined above.
Data-dependent acquisition (DDA)–MS analysis. Proteins from the spike
pulldown experiments were subject to in-solution tryptic digestion and C18 clean-
up as described above. Tryptic peptides were analyzed by LC–MS/MS. An UltiMate
3000 HPLC system (Thermo Scientific) with a nanoflow selector was coupled via
an EASY-Spray Source (Thermo Scientific) to a Q Exactive HF mass spectrometer
(Thermo Scientific). Peptides were injected onto a C18 trap cartridge (Thermo
Scientific, 160454) at a flow rate of 25 µL/min for 1 min, using 0.1% FA (aq).
Peptides were eluted from the trap cartridge and separated on an analytical column
(EASY-Spray C18 column, 75 µm × 50 cm, Thermo Scientific, ES803A, at 45 °C) at
a flow rate of 0.25 µL/min using the following gradient: 0–1 min, 1% B; 1–6 min,
1–6% B; 6–40 min, 6–18% B; 40–70 min, 18–35% B; 70–80 min, 35–45% B; 80–81
min, 45–99% B; 81–89.8 min, 99% B; 89.8–90 min, 99–1% B; 90–120 min, 1% B.
Mobile phase A was 0.1% FA (aq) and mobile phase B was 80% ACN, 0.1% FA
(aq). Precursor MS1 spectra were acquired using Orbitrap detection (resolution
60,000 at 200 m/z, scan range 350–1600). Data-dependent MS2 spectra of the most
abundant precursor ions were obtained after higher-energy C-trap dissociation and
Orbitrap detection (resolution 15,000 at 200 m/z) with TopN mode (loop count 15)
and dynamic exclusion (duration 40 s) enabled.
MS database search for DDA–MS analysis. Proteome Discoverer software
(version 2.3.0.523, Thermo Scientific) was used to search raw SARS-CoV-2 spike
glycoprotein pulldown data files against a human database (UniProtKB/Swiss-Prot
version 2020 01, 20,365 protein entries) supplemented with SARS-CoV-2 spike
glycoprotein (1 protein entry) using Mascot (version 2.6.0, Matrix Science). The
mass tolerance was set at 10 ppm for precursor ions and 0.02 Da for fragment ions.
Trypsin was used as the digestion enzyme with up to two missed cleavages being
allowed. Carbamidomethylation of cysteines and oxidation of methionine residues
were chosen as fixed and variable modifications, respectively.
Cell culture. HEK293T cells (ATCC CRL-3216) were cultured in Dulbecco’s
modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supple-
mented with 10% FBS (Life Technologies) plus a final concentration of 100 IU/ml
penicillin and 100 μg/ml streptomycin, or without antibiotics where required for
transfections. Vero (WHO) Clone 118 cells (ECACC 88020401) were cultured in
Dulbecco’s modified Eagle medium (DMEM, Life Technologies) with 1 g/L glucose
(Life Technologies) supplemented with 10% heat-inactivated FBS (Life Technolo-
gies) plus a final concentration of 100 IU/ml penicillin and 100 μg/ml streptomycin,
or without antibiotics where required for transfection. Cells were incubated at
37 °C, 5% CO2.
Plasmids. Human ACE2-coding plasmid (Addgene, 1786), pLVTHM/GFP
(Addgene, 12247), psPAX2 (Addgene, 12260), pMD2.G (Addgene, 12259) were
obtained from Addgene and pCMV6-LGALS3BP (OriGene, RC204918) from
ORIGENE. pcDNA3, pAAV-CMV-GFP and pAVV-mCherry were obtained from
L. Zentilin (Molecular Medicine Lab, International Centre for Genetic Engineering
and Biotechnology, Trieste, Italy). The SARS-CoV-2 spike coding sequence (NCBI
accession number NC_045512.2) was codon-optimized and synthesized with a V-5
tag at the C-terminus and then cloned in to the pZac 2.1 AAV (pAAV-Spike)
vector under the control of a cytomegalovirus promoter. The last 19 amino acids at
the C-terminus of the SARS-CoV-2 spike protein contain an endoplasmic reticu-
lum retention sequence, which reduces the yield of spike-pseudoparticle produc-
tion. For pseudoparticle production, a pAA-Spike-d19-V5 expression vector was
generated, deleting the 19 amino acid endoplasmic reticulum retention signal
through PCR amplification (primer sequences are listed in Supplementary Table 9),
and cloned into the pAAV-Spike-V5 vector. The construct was verified by
sequencing.
Antibodies. Antibodies against the following proteins were used: ACE2 (Abcam,
ab15348), LGALS3BP (Abcam, ab217572), SARS-CoV-2 spike protein (GeneTex
GTX632604), V5-488 (Thermo Fisher Scientific, 377500A488), α-tubulin (Sigma-
Aldrich T5168), mouse-HRP (Abcam ab6789) and rabbit-HRP (Abcam ab205718).
Small interfering RNA and SARS-CoV-2-spike coding plasmid transfections.
SiRNAs (siACE2, M-005755-00-0005; siNT1, non-targeting siRNA) were reverse
transfected in 96 well plates, with the transfection reagent (Lipofectamine RNAi-
MAX, Life Technologies) and siRNAs (25 nM) diluted in Opti-MEM (Life Tech-
nologies) after 5 min of incubation at room temperature. The transfection mixes
were incubated for 30 min at room temperature and then added to the 96-well
plates (CellCarrierUltra 96, Perkin Elmer). Reverse transfection of plasmids
(pcDNA3, pmCherry, pLGALS3BP) was performed in 96-well plates, using a dif-
ferent amount for each plasmid. Totally, 25 ng to 100 ng of plasmids were diluted
in 25 µL of Opti-MEM (Life Technologies) and mixed with the transfection reagent
(FuGENE HD, Promega) using a ratio of 1 µg pDNA: 3 µl FugeneHD. The
transfection mixes were incubated for 25 min at room temperature and added to
the 96-well plates (CellCarrierUltra 96, Perkin Elmer). After 30 min, 6.5 × 103 Vero
cells or 8 × 103 HEK293-ACE2 cells were seeded in each well. 24 h after trans-
fection, 75 ng of either pEC117-Spike-V5 or pCMV-EGFP expression plasmids
were transfected using a standard forward transfection protocol. After 24 h, cells
were fixed in 4% PFA and processed for immunofluorescence.
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Pseudoparticle production and transduction. An HIV-1-based replication-
deficient lentiviral system was used to produce VSV-G and SARS-CoV-2 spike
pseudotyped particles92. The particles were produced in HEK293T cells by co-
transfecting 10 μg PLVTHM(GFP) plasmid, 5 μg psPAX2 (packing vector) and 5 μg
pMD2.G (VSV-G pseudotyped particles) or pAAV-SΔc19 (Spike pseudotyped
particles) using FugeneHD (Promega) transfection reagent in a ratio of 1 μg pDNA:
3 μl FugeneHD92. Viral supernatants were collected 48 h after transfection and
centrifuged at 2105×g for 10 min at 4 °C. The supernatants were then filtered with a
0.45 μm pore size filter, aliquoted and stored at −80 °C. For pseudoparticle
transduction, 24 h before transduction, both siRNAs and plasmids were transfected
into the HEK293 cell expressing ACE2 by using a reverse transfection protocol. 24
h after transfection, equal amounts of VSV-G or Spike pseudoparticles were added
to each treatment. After 36 h, cells were fixed, nuclei were labelled with Hoechst
and assessed for pseudoparticle transduction efficiency based on GFP expression.
Immunofluorescence. After fixation in 4% PFA for 10 min at room temperature,
cells were washed two times in 100 µL/well (96-well plate) of 1× PBS and then
permeabilized in same volumes of 0.1% Triton X100 (Sigma-Aldrich 1086431000)
for 10 min at room temperature. Cells were then washed two times with 1× PBS
and blocked in 2% bovine serum albumin (BSA) for 1 h at room temperature. After
blocking, 45 µL/well (96-well plate) of diluted primary antibody (1:500 in 1% BSA
SARS-CoV-2 spike antibody or V5-488, and Flag/LGALS3BP antibody were added
to each well and incubated overnight at 4 °C. Cells were then washed two times in
1× PBS, the 1× PBS was removed and 45 µL/well of diluted (1:500 in 1% BSA)
secondary antibodies were added to each well and incubated 2 h at room tem-
perature. Cells were then washed two times in 1× PBS. Nuclear staining was
performed by Hoechst 33342 (1:5000) according to manufacturer’s instruction.
Image acquisition and analysis of syncytia and pseudoparticle entry. Syncytia:
Image acquisition was performed using the Operetta CLS high content screening
microscope (Perkin Elmer) with a Zeiss 20× (NA= 0.80) objective, a total of 25
fields were acquired per wavelength, well and replicate (~10,000–15,000 cells per
well and replicate). Images were subsequently analyzed, using the Harmony soft-
ware (version 4.9, PerkinElmer). Images were first flatfield-corrected and nuclei
were segmented using the “Find Nuclei” analysis module (Harmony software,
version 4.9, PerkinElmer). The thresholds for image segmentation were adjusted
according to the signal to background ratio. The splitting coefficient was set in
order to avoid splitting of overlapping nuclei (fused cells). The intensity of the
green fluorescence (spike/GFP) was calculated using the ‘Calculate Intensity
Properties’ module (Harmony software, version 4.9, PerkinElmer). All cells that
scored a nuclear area greater than 4 times the average area of a single nucleus and
simultaneously showed a green signal (spike) in the cytoplasm were considered as
syncytia. In the case of manual quantification of syncytia, >3 fused nuclei were
counted as syncytia, when the cytoplasm showed a green signal (spike). Data are
expressed as the percentage of fused cells by calculating the average number of
fused cells normalized to the total number of cells per well. Pseudoparticle entry:
Mean intensities of the segmented nucleus in the DAPI channel and the Hoechst
channel for each nucleus across all fields were extracted. Each assay plate included
siACE2 (siRNA targeting ACE2) as a positive control as well as pcDNA3 and
siNT1 (non-targeting siRNA) as negative controls. Briefly, nuclei were segmented
based on Hoechst staining, and cells were then classified as positive or negative
depending on the GFP signal. Data are expressed as the percentage of GFP-positive
cells by calculating the average number of GFP-positive cells normalized to the
total number of cells per well.
Western blotting. After 48 h of transfection with siRNAs or plasmids, super-
natants were collected, and cell debris was removed by centrifugation. HEK293 cell
membranes were isolated using the Mem-PERTM Plus Membrane Protein
Extraction Kit (Thermo Fisher, 89842), according to the manufacturer’s instruc-
tions. Equal amounts of total cellular proteins (15–20 μg), as measured by BCA
assay (Thermo Fisher, 23227), were resolved by electrophoresis in 4–20% gradient
polyacrylamide gels (Mini-PROTEAN, Biorad) and transferred to nitrocellulose/
PVDF membranes (GE Healthcare). Membranes were blocked at room tempera-
ture for 60 min with PBST (PBS+ 0.1% Tween-20) containing 5% skim milk
powder (Cell signalling, 9999). Blots were then incubated (4 °C, overnight) with
primary antibodies against ACE2 (diluted 1:1000), LGALS3BP (diluted 1:1000) and
α-tubulin (diluted 1:10,000). Blots were then washed three times (8 min each) with
PBST. For standard Western blotting detection, blots were incubated with either an
anti-rabbit HRP-conjugated antibody (1:5000) or an anti-mouse HRP-conjugated
antibody (1:10,000) for 1 h at room temperature. After washing three times at room
temperature with PBST (10 min each), blots were developed with Enhanced
Chemiluminescence (ECL, Amersham).
Machine learning. Machine learning was deployed to identify a prognostic clas-
sifier for COVID-19 ICU patients based on 27 clinical variables, RNAemia, as well
as ELISA measurements of candidates selected from the literature (PTX331–34,
RAGE28–30, and LGALS3BP). To ascertain the translational value of our machine
learning results, we did not include our DIA MS-based data. The RNAemia feature
was defined as a binary feature that takes a true value when RNAemia was present
within six days upon admission to ICU. Feature selection was undertaken using an
ensemble approach - feature filter for singleton variables followed by a wrapper
method to evaluate binary and triplet combinations of these shortlisted singleton
features (Supplementary Fig. 7). Mann–Whitney U test of statistical significance
(P value < 0.05) was used as feature selection criterium for singleton markers
(Fig. 4b, Supplementary Table 1). Binary and triplet combinatorial feature search
was performed using wrapper feature selection93 with support vector machine
(SVM) classifier using radial basis function (RBF) kernel. Feature combinations
were evaluated using the average of sensitivity, PPV and area under the receiver
operating characteristic curve (ROC AUC) metrics. Although the F1-score, i.e., the
harmonic mean of sensitivity and precision (PPV), is a commonly used evaluation
metric for imbalanced data, the drawback is that F1-score does not reflect the
correct classification of the majority class, i.e., true negatives. Combining ROC
AUC along with sensitivity and PPV addresses this limitation of standalone usage
of the F1-score. SVM uses hyperplane (decision surface) leveraging only a per-
centage of training samples (support vectors), thus offering high generalization
ability attributed to its near impervious characteristic to new samples94. Combi-
nations were restricted to a maximum of triplets to enhance the ease of clinical
implementation and avoid the risk of overfitting. In addition, tenfold cross-
validation along with leave-one-out validation was used to avoid overfitting and
test model generalization. The SVM Synthetic Minority Oversampling Technique
was used to prevent the learning bias of SVM RBF towards the majority class95.
Tuning of the SVM RBF external parameter i.e., C was performed using grid
search. The Scikit-learn default i.e., “scale” was used for the SVM RBF gamma
parameter96. A permutation test was performed to evaluate the null hypothesis that
the classifier performance is by chance i.e., input variables and outcome labels are
independent97. Hence, rejection of the null hypothesis implies that the classifier has
found a real class structure (pattern) in the data. For technical validation of our
“Age, RNAemia” model based on SVM RBF, we employed a permutation test for
statistical significance of the classifier performance; and stability of feature
importance in an alternate machine learning feature ranking model, i.e., Random
forest with resampling. Age and RNAemia were ranked among the top five most
important features based on mean importance across 100 resampling cycles of
sensitivity analysis. A permutation test with 50 permutes i.e., repeating the clas-
sification procedure after random permuting of the outcome labels returned a
significant P value (Supplementary Fig. 8). The implementation of machine
learning was done using Scikit-learn 0.23.2 python package96.
Statistical analysis. All statistical analyses were two-tailed. Shapiro–Wilk nor-
mality test was extensively applied in proteomics and clinical data and some fea-
tures were found to be not normally distributed. For this reason, nonparametric
methods were used throughout the manuscript for differential expression analysis
and correlation analysis. Mann-Whitney U significance test was used for con-
tinuous variables and Fisher exact test for binary variables in Supplementary
Tables 1, 3 and 4. Statistical comparisons on MS and ELISA data were performed
applying the nonparametric Mann–Whitney U test on the preprocessed data
removing the residuals of age and sex from fitted linear models. Spike pulldown
data were analyzed by paired or unpaired Student’s t-tests as appropriate, because
of the low sample size which makes the use of nonparametric tests not suitable.
Timepoint comparisons were performed using the nonparametric Kruskal–Wallis
test. Linear mixed models analysis was performed to further evaluate the combi-
natorial effect of time and RNAemia, and time and outcome respectively in the
expression of significant proteins, correcting in all cases for age and sex. Corre-
lations between continuous variables were analyzed using Spearman correlation.
Correlations between categorical and continuous variables were examined using
point-biserial correlation. Correlations between categorical variables were exam-
ined using Cohen’s Kappa correlation. Anti-SARS-CoV-2 antibody data and tra-
jectories of protein clusters were fitted using Generalized Alternative
Models (GAM), with P values reporting the effect of RNAemia or mortality in the
model because the trajectories of the antibody data have been demonstrated to be
nonlinear and the same was observed for the protein clusters. Survival analysis was
performed using Cox regression and Kaplan–Meier plots leveraging the R “survi-
val” package. As two groups, i.e., low and high risk were being compared, no
adjustments for multiple comparisons were performed in the Kaplan–Meier ana-
lysis. All features were scaled to a mean of zero and a standard deviation of one.
Proteins quantified by MS and clinical features with missing values ≥30% were
dropped and not used for data analysis. This resulted in two clinical variables being
dropped, i.e., eosinophils and basophils. The remaining features were imputed, as
applicable, using KNN based imputation with K= 5 (Supplementary Table 11)91.
To validate DIA–MS findings, a publicly available proximity-extension assay
proteomics-based dataset was analyzed (Data provided by the MGH Emergency
Department COVID-19 Cohort (Filbin, Goldberg, Hacohen) with Olink
Proteomics)38. Differential expression analysis of proteins in survivors and non-
survivors 28-days after hospitalization within the Olink dataset38 was achieved
through the Ebayes method of the limma package since RQ values of Olink
measurements were normally distributed. Benjamini-Hochberg’s FDR corrected
q-values were calculated to correct for multiple testing in all parts of the analysis:
differential expression, correlation, survival. Statistical analysis and associated fig-
ures were generated with R programming environment (version 4.02), Python
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programming environment (version 3.8.6) and GraphPad software (version 8.4.3).
Schematic diagrams were created with Biorender.com.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available within
the article and its Supplementary Data. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the
dataset identifiers PXD024026 and PXD024089 (https://www.ebi.ac.uk/pride/). We used
the following human protein database: UniProtKB/Swiss-Prot version 2020 01, 20,365
protein entries (https://www.uniprot.org).
The external validation data was provided by the MGH Emergency Department
COVID-19 Cohort (Filbin, Goldberg, Hacohen) with Olink Proteomics38 (https://info.
olink.com/mgh-covid-study-overview-page?utm_campaign=Broad%2520%2520Explore
%2520Covid%2520Study&utm_source=research-gate&utm_medium=MGH%
2520post). Source data are provided with this paper.
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